Mirum Pharmaceuticals (MIRM) said late Tuesday it plans to offer $600 million of senior notes due 2032.
The company will grant the initial buyers a 13-day overallotment option to buy up to an additional $90 million of the notes, according to a statement.
Net proceeds will be used to cover note exchange transactions and for general corporate purposes, the company said.